Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index; 5 of the 13 sources its claims cite were checked for support.
Abstract
A library of drugs that are in clinical trials or use was screened for inhibitors of hypoxia-inducible factor 1 (HIF-1). Twenty drugs inhibited HIF-1-dependent gene transcription by >88% at a concentration of 0.4 microM. Eleven of these drugs were cardiac glycosides, including digoxin, ouabain, and proscillaridin A, which inhibited HIF-1alpha protein synthesis and expression of HIF-1 target genes in cancer cells. Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within one week. Enforced expression of HIF-1alpha by transfection was not inhibited by digoxin, and xenografts derived from these cells were resistant to the anti-tumor effects of digoxin, demonstrating that HIF-1 is a critical target of digoxin for cancer therapy.
Overview
CoChat Summary
TL;DR
A screen of 3,120 clinically used or trial drugs identified cardiac glycosides, including digoxin, as potent inhibitors of HIF-1α protein synthesis. Digoxin blocked HIF-1 target gene expression and inhibited tumor xenograft growth, with resistance in cells expressing HIF-1α from a transfected vector lacking HIF-1α mRNA untranslated regions.
Key findings
- In a Hep3B-c1 reporter screen, 336 of 3,120 drugs reduced hypoxia-induced firefly/Renilla luciferase activity by ≥50% at 10 µM; after re-screening, the top 20 drugs caused ≥88% inhibition at 0.4 µM, and 11 of these 20 were cardiac glycosides, including digoxin, ouabain, and proscillaridin A.
- Cardiac glycosides inhibited hypoxia-induced HIF-1α and HIF-2α protein expression at concentrations ≥50 nM and decreased mRNA levels of HIF-1 target genes HK1, HK2, and GLUT1 at 1% O2, without inhibiting HIF-1α mRNA.
- Digoxin inhibited HIF-1α protein synthesis independently of the PHD-VHL-proteasome pathway, mTOR/RPS6, Na+/K+ ATPase α1, and topoisomerases; pulse-labeling showed digoxin reduced de novo HIF-1α synthesis by 73% while overall protein synthesis was inhibited by only 19%.
- In SCID mouse xenografts, daily i.p. digoxin at 0.5 or 2 mg/kg inhibited P493-Myc tumor growth dose-dependently; 2 mg/kg inhibited PC3 tumor growth, and delayed treatment of established tumors (mean volume 100 mm3) caused growth arrest within 7 days. PC3-CA5 xenografts expressing constitutively active HIF-1α were resistant to digoxin’s anti-tumor effect.
Methods
- Cell-based screen using Hep3B-c1 cells stably transfected with an HRE-driven firefly luciferase reporter and a constitutive Renilla luciferase reporter; the Hopkins Drug Library of 3,120 FDA-approved or phase II drugs was screened at 10 µM, then re-screened at 2 µM and 0.4 µM.
- Mechanistic assays included immunoblotting for HIF-1α/HIF-2α, quantitative real-time RT-PCR for HIF-1 target mRNAs, [35S]methionine/cysteine pulse-labeling with HIF-1α immunoprecipitation, shRNA knockdown of Na+/K+ ATPase α1 and topoisomerases, flow cytometry, and annexin V staining.
- In vivo studies used SCID mice bearing P493-Myc, PC3-EV, or PC3-CA5 xenografts; digoxin was administered by daily intraperitoneal injection, with tumor volume, body weight, tumor HIF-1α protein, and HIF-1 target gene mRNAs assessed.
Limitations
- The paper states that digoxin has both HIF-1α-dependent and HIF-1α-independent effects on cell growth, based on PC3-CA5 cells growing similarly to vehicle-treated PC3-EV cells.
- Evident from the text: the mechanistic and in vivo work relies on specific cell lines and SCID mouse xenograft models, with no human clinical outcomes reported.
- The provided text is truncated before the end of the Discussion, so any additional limitations stated there are not available.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 4 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIF-1 also controls the expression of genes involved in tumor cell immor- talization, stem cell maintenance/de-differentiation, genetic in- stability, autocrine growth, invasion/metastasis, and treatment failure (6, 7).”
What the sources say
- Not checked — no full text of the sourcecites [6] matched to “Evaluation of HIF-1 inhibitors as anticancer agents” (2007) source
- Partly supportedcites [7] matched to “The role of hypoxia-inducible factors in tumorigenesis” (2008) sourceExperimental — accuracy not yet measured
The Figure 3 caption (Angiogenesis section; page not provided) says HIF-regulated genes contribute to proliferation, invasion, and metastasis, and the Differentiation discussion links HIF signaling to an undifferentiated state. But the review does not establish that HIF-1 controls genes for every listed outcome: it attributes direct Oct4 regulation to HIF-2, does not substantiate immortalization or genetic instability, and describes HIF-1’s effects on radiotherapy response as mixed rather than simply causing treatment failure. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Digitoxin inhibited the development of skin pap- illomas in mice treated with dimethylbenzanthracene and tetra- decanoylphorbol ester (34).”
What the sources say
- Supportedcites [34] matched to “Anti-tumor Promoting Activities of Natural Products. II. Inhibitory Effects of Digitoxin on Two-Stage Carcinogenesis of Mouse Skin Tumors and Mouse Pulmonary Tumors.” (1993) source
The Results and Discussion (p. 1) report that digitoxin delayed skin papilloma formation and reduced both the proportion of mice bearing papillomas and the average number per mouse. The figure caption on the same page identifies DMBA as the initiator and TPA as the promoter. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The growth of digoxin-treated PC3-CA5 cells was similar to that of vehicle-treated PC3-EV cells.”
§ 4 h pretreatment > 1.00 0.31 0.270.12
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When Hep3B-c1 cells were cultured under hypoxic conditions (1% O2), the ratio of firefly/Renilla luciferase activity was ten-fold higher than when the cells were cultured under nonhy- poxic conditions (20% O2) for 24 h (Fig. 1B).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were obtained in Hep3B cells treated with 100 nM digoxin (Fig. 1G).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 27 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, pharmacologic depletion of HIF1α by small molecules PX478 and Digoxin41,42 also produced similar results in T and NK cells (Fig. 4g, h and Fig. S5f, g, h).”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Digoxin, which is currently passing phase I clinical trials, was reported to inhibit established tumor xenografts with no effect on the growth of constitutively expressing HIF-1 xenografts.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vivo, digoxin inhibits tumor growth and suppresses lung metastasis in orthotopic breast cancer models [295,297].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In HepB cells, these agents reduced both HIF-1α and HIF-2α protein levels without altering HIF1A mRNA, indicating post-transcriptional regulation [295].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredIn the citing paper
“One significant hurdle for the use of these compounds, however, is the lack of specificity of these compounds for specific blockade of HIF (such as digoxin, acriflavine, and 17-AAG) identified to date [124–126].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [125]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · cited 1×
“HIF-1 is a heterodimeric protein that is composed of O2regulated HIF-1 and constitutively expressed HIF-1 subunits (8, 9).”
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“VHL loss-of-function results in constitutive expression of HIF-1 in the majority of clear cell renal carcinomas (11).”
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“Under normoxic conditions, HIF-1 is hydroxylated on proline residue 564 and/or 402 by proline hydroxylase domain protein 2 (PHD2), which is required for the binding of the von Hippel-Lindau protein (VHL), the recognition subunit of an E3 ubiquitin-protein ligase that targets HIF-1 for proteasomal degradation (10).”
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
(1999) · PubMed · Cited by 2,204
Self-citationPurification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Self-citationRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“Whereas VHL loss-of-function leading to dysregulated HIF-1 expression is restricted to renal cell carcinoma and cerebellar hemangioblastoma, many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Self-citationTalks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Cited by
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Self-citationControl of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595
“Other transcription factors have been identified to contribute to the induction of IL-17A in TH17- polarized cells: Runx1 (Zhang et al., 2008), BATF (Schraml et al.”
Self-citationHypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
“Drugs that inhibit the translation of HIF-1α mRNA into protein include: (i) mTOR inhibitors, such as rapamycin, temsirolimus (CCI-779), and everolimus (RAD-001) [50]; (ii) cardiac glycosides, such as digoxin [51], which have been used for decades to treat heart disease; (iii) microtubule targeting agents, such as 2-me…”
BackgroundSelf-citationPyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463
“LDHA, PDK1, and GLUT1 protein levels were also significantly reduced in HeLa cells transduced with shPKM2 retrovirus, which was comparable to the effect of treatment with digoxin (Figure 7B and Figure S6B), a drug that inhibits HIF-1a synthesis (Zhang et al., 2008).”
ResultSelf-citationHypoxia-Induced Angiogenesis: Good and Evil
Krock, B. L., Skuli, N., & Simon, M. C. (2011) · Genes & Cancer · doi:10.1177/1947601911423654 · Cited by 1,180
Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
Semenza, G. L. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104720 · Cited by 1,159
Self-citationOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993
Self-citationHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
Self-citationTherapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“HIF-1 is directly involved in regulating mitochondrial autophagy by inducing expression of the BH3-only proteins BNIP3 andBNIP3L,whichpromotes release of Beclin-1, a major autophagy regulator (Zhang et al., 2008a; Bellot et al., 2009).”
BackgroundLee, K.-M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L., Hutchinson, K. E., Nixon, M. J., Estrada, M. V., Sánchez, V., Sanders, M. E., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.009 · Cited by 650
“To complement these studies with a pharmacological approach, we used digoxin, which inhibits translation of HIF-1a (Zhang et al., 2008).”
MethodSelf-citationPrabhakar, N. R., & Semenza, G. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00030.2011 · Cited by 641
“This hypothesis was tested by the daily administration of digoxin, a cardiac glycoside that has been used to treat congestive heart failure and cardiac arrythmias for decades, which inhibits the synthesis of HIF-1 protein (379).”
MethodHypoxia-Inducible Factor 1 and Cardiovascular Disease
Semenza, G. L. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170322 · Cited by 608
Self-citationHypoxia-inducible factors: cancer progression and clinical translation
Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 580
“HIF inhibitors that have shown antitumor activity in mouse tumor models include acriflavine (47), digoxin (106), echinomycin (156), the HSP90 inhibitors 17-allylaminogeldanamycin (157) and ganetespib (158), 2-methoxyestradiol (159), PX-478 (160), and YC-1 (161).”
BackgroundSelf-citationHIF‐1 at the crossroads of hypoxia, inflammation, and cancer
Balamurugan, K. (2016) · International Journal of Cancer · doi:10.1002/ijc.29519 · Cited by 572
Molecular pathogenesis of retinal and choroidal vascular diseases
Campochiaro, P. A. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.002 · Cited by 545
“High throughput screening of a drug library with a reporter cell line for HIF-1 transcriptional activity has determined that digoxin and doxorubicin are strong inhibitors of HIF-1 activity (Lee et al., 2009; Zhang et al., 2008).”
BackgroundShukla, S. K., Purohit, V., Mehla, K., Gunda, V., Chaika, N. V., Vernucci, E., King, R. J., Abrego, J., Goode, G. D., Dasgupta, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.004 · Cited by 540
“HIF-1a binding was further induced under hypoxic conditions and diminished by digoxin, a translational inhibitor of HIF-1a (Zhang et al., 2008).”
BackgroundHypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling
Rey, S., & Semenza, G. L. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq045 · Cited by 540
Self-citationReciprocal Regulation of HIF-1α and LincRNA-p21 Modulates the Warburg Effect
Yang, F., Zhang, H., Mei, Y., & Wu, M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.11.004 · Cited by 510
“Moreover, when HIF-1a activity was inhibited by treatment with digoxin (a potent inhibitor of HIF-1a [Zhang et al., 2008]) or by reducing HIF-1a expression using its specific shRNA, lincRNA-p21 knockdown failed to show any effect on wild-type reporter activity under hypoxia (Figures 2E, 2F, S2A,…”
BackgroundSelf-citationCancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
“Other compounds belonging to cardiac glycosides [127], steroids [128], topoisomerase inhibitors [129], and microtubule binding agents [130] show the inhibitory effect of translation rate of HIF mRNA by different mechanisms.”
BackgroundSamanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
Self-citationRetractedRETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
Self-citationRetractedCardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003807 · Cited by 423
Gomes, A. L., Teijeiro, A., Burén, S., Tummala, K. S., Yilmaz, M., Waisman, A., Theurillat, J.-P., Perna, C., & Djouder, N. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.020 · Cited by 401
Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Shim, J. S., & Liu, J. O. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9224 · Cited by 382
“as inhibition of Na+/K+-ATPase and HIF-1α synthesis [62, 63].”
BackgroundSelf-citationCampochiaro, P. A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-0993-5 · Cited by 386
“ity of HIF-1 [43] and strongly suppresses retinal and choroidal NV [44].”
Integrating canonical and metabolic signalling programmes in the regulation of T cell responses
Pollizzi, K. N., & Powell, J. D. (2014) · Nature Reviews Immunology · doi:10.1038/nri3701 · Cited by 379
Bar, E. E., Lin, A., Mahairaki, V., Matsui, W., & Eberhart, C. G. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091021 · Cited by 373
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases
Eltzschig, H. K., Bratton, D. L., & Colgan, S. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4422 · Cited by 366
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
“eradicate established xenograft tumors by suppressing HIF-1α and HIF-2α expression (77).”
BackgroundZhang, H., Wong, C. C. L., Wei, H., Gilkes, D. M., Korangath, P., Chaturvedi, P., Schito, L., Chen, J., Krishnamachary, B., Winnard, P. T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.365 · Cited by 326
“To complement this genetic approach, in which HIF activity was inhibited in cancer cells before implantation, we treated mice bearing established tumors with digoxin, which inhibits translation of HIF-1a and HIF-2a mRNA into protein by an mTOR-independent mechanism (Zhang et al., 2008).”
BackgroundMethodInfluentialSelf-citationRetractedHypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer
Bao, M. H.-R., & Wong, C. C.-L. (2021) · Cells · doi:10.3390/cells10071715 · Cited by 316
Joseph, J. V., Conroy, S., Pavlov, K., Sontakke, P., Tomar, T., Eggens-Meijer, E., Balasubramaniyan, V., Wagemakers, M., den Dunnen, W. F. A., & Kruyt, F. A. E. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.010 · Cited by 302
RETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis
Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3963 · Cited by 296
Self-citationRetractedIn silico repositioning of approved drugs for rare and neglected diseases
Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 288
Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
Self-citationBai, R., Li, Y., Jian, L., Yang, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 279
“Digoxin is also able to inhibit HIF-1α protein translation and HIF-2α mRNA expression, leading to anti- tumor effects [223].”
BackgroundHIF and the Lung: Role of Hypoxia-inducible Factors in Pulmonary Development and Disease
Shimoda, L. A., & Semenza, G. L. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1393pp · Cited by 277
Self-citationAnticancer steroids: linking natural and semi-synthetic compounds
Salvador, J. A. R., Carvalho, J. F. S., Neves, M. A. C., Silvestre, S. M., Leitão, A. J., Silva, M. M. C., & Sá e Melo, M. L. (2013) · Nat. Prod. Rep. · doi:10.1039/c2np20082a · Cited by 276
Role of hypoxia-inducible factors in breast cancer metastasis
Gilkes, D. M., & Semenza, G. L. (2013) · Future Oncology · doi:10.2217/fon.13.92 · Cited by 274
Self-citationLu, H., Samanta, D., Xiang, L., Zhang, H., Hu, H., Chen, I., Bullen, J. W., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513433112 · Cited by 269
“Coadministration of a HIF-1 inhibitor, such as digoxin (10, 23, 50) or ganetespib (51), with cytotoxic chemotherapy may be particularly effective because of the multiple mechanisms by which HIF-1 promotes BCSCs and other aspects of cancer progression (52).”
BackgroundSelf-citationDevelopment of HIF‐1 inhibitors for cancer therapy
Onnis, B., Rapisarda, A., & Melillo, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00876.x · Cited by 268
Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis
Gilkes, D. M., Bajpai, S., Wong, C. C., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0629 · Cited by 252
“In addition, MDA-MB-231 cells were treated with digoxin, which inhibits HIF-1a protein expression (57).”
Self-citationRetractedHypoxia-inducible factor 1 and breast cancer metastasis
Liu, Z.-J., Semenza, G. L., & Zhang, H.-F. (2015) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b1400221 · Cited by 252
Self-citationMiller, S. C., Huang, R., Sakamuru, S., Shukla, S. J., Attene-Ramos, M. S., Shinn, P., Van Leer, D., Leister, W., Austin, C. P., & Xia, M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.021 · Cited by 250
“The potential anti-cancer mechanisms of these drugs have been linked to the inhibition of HIF-1α (hypoxia inducible factor 1α) synthesis in Hep3B cells, human liver carcinoma cells [35], the reduction of the p53 levels via the inhibition of p53 protein synthesis in lung cancer cells [36], the inhibition of Miller et a…”
BackgroundHypoxia-Inducible Factors and Cancer
Jun, J. C., Rathore, A., Younas, H., Gilkes, D., & Polotsky, V. Y. (2017) · Current Sleep Medicine Reports · doi:10.1007/s40675-017-0062-7 · Cited by 248
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
“Daily treatment with digoxin (2 mg kg −1 ) limits growth of P493-Myc cell line-derived tumour xenografts in vivo in murine models 141 .”
The Warburg effect: Insights from the past decade
Upadhyay, M., Samal, J., Kandpal, M., Singh, O. V., & Vivekanandan, P. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.11.003 · Cited by 243
Chaperone-mediated Autophagy Targets Hypoxia-inducible Factor-1α (HIF-1α) for Lysosomal Degradation
Hubbi, M. E., Hu, H., Kshitiz, Ahmed, I., Levchenko, A., & Semenza, G. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.414771 · Cited by 242
“Cardiac glycosides, such as digoxin, inhibit HIF-1 activity by decreasing HIF-1 protein levels (41).”
BackgroundSelf-citationChiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Chaturvedi, P., Gilkes, D. M., Wong, C. C. L., Kshitiz, Luo, W., Zhang, H., Wei, H., Takano, N., Schito, L., Levchenko, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64993 · Cited by 238
“When the tumors had grown to 200 mm3, the mice received daily intraperitoneal injections of either saline or digoxin (2 mg/kg) to inhibit HIF activity (27, 28, 35).”
Self-citationMcNamee, E. N., Korns Johnson, D., Homann, D., & Clambey, E. T. (2013) · Immunologic Research · doi:10.1007/s12026-012-8349-8 · Cited by 234
Drug repositioning by structure-based virtual screening
Ma, D.-L., Chan, D. S.-H., & Leung, C.-H. (2013) · Chemical Society Reviews · doi:10.1039/c2cs35357a · Cited by 232
Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE
Caielli, S., Cardenas, J., de Jesus, A. A., Baisch, J., Walters, L., Blanck, J. P., Balasubramanian, P., Stagnar, C., Ohouo, M., Hong, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.021 · Cited by 228
Wong, C. C.-L., Zhang, H., Gilkes, D. M., Chen, J., Wei, H., Chaturvedi, P., Hubbi, M. E., & Semenza, G. L. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0855-y · Cited by 225
“Digoxin [18] and acriflavine [19] are HIF-1”
Self-citationInhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification
Agarwal, S., Loder, S., Brownley, C., Cholok, D., Mangiavini, L., Li, J., Breuler, C., Sung, H. H., Li, S., Ranganathan, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515397113 · Cited by 223
Brownfoot, F. C., Hastie, R., Hannan, N. J., Cannon, P., Tuohey, L., Parry, L. J., Senadheera, S., Illanes, S. E., Kaitu’u-Lino, T. J., & Tong, S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.019 · Cited by 222
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy
Gupta, S., Roy, A., & Dwarakanath, B. S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00068 · Cited by 218
“Further, inhibition of HIF1 transcription by flavopiridol (263), dimerization and synthesis by acriflavine and digoxin (264, 265) and induction of HIF1 degradation by trichostatin A, a histone deacetylase inhibitor (266) have been investigated as therapeutic approaches (Table 1).”
BackgroundMetabolic control of the Treg/Th17 axis
Barbi, J., Pardoll, D., & Pan, F. (2013) · Immunological Reviews · doi:10.1111/imr.12029 · Cited by 217
“Nevertheless, it is tempting to speculate on the possibility that the Th17suppressing activity of digoxin could be linked to its negative effects on HIF-1 (55).”
BackgroundMolecular mechanisms mediating metastasis of hypoxic breast cancer cells
Semenza, G. L. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.08.001 · Cited by 217
Self-citationSitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215
“Promising inhibitors of HIF-1a, including digoxin and acriflavine (65, 66), were shown to decrease lung metastasis in an orthotopic breast cancer model.”
BackgroundTargeting the hypoxia-inducible factor (HIF) pathway in cancer
Poon, E., Harris, A. L., & Ashcroft, M. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001173 · Cited by 213
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Belikoff, B., Schreiber, T. H., Sethumadhavan, S., Abbott, R., Philbrook, P., Thayer, M., Shujia, D., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1189-3 · Cited by 211
“, HIF-1α-dependent increase in EPO, VEGF and neovascularization [1, 7, 19].”
BackgroundYuan, G., Khan, S. A., Luo, W., Nanduri, J., Semenza, G. L., & Prabhakar, N. R. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22640 · Cited by 201
Self-citationSemenza, G. L. (2013) · Oncogene · doi:10.1038/onc.2012.578 · Cited by 201
Self-citationHypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia
Geng, H., Harvey, C. T., Pittsenbarger, J., Liu, Q., Beer, T. M., Xue, C., & Qian, D. Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257055 · Cited by 197
Self-citationHaiser, H. J., Seim, K. L., Balskus, E. P., & Turnbaugh, P. J. (2014) · Gut Microbes · doi:10.4161/gmic.27915 · Cited by 197
Ma, S., Zhao, Y., Lee, W. C., Ong, L.-T., Lee, P. L., Jiang, Z., Oguz, G., Niu, Z., Liu, M., Goh, J. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31764-9 · Cited by 200
Hypoxic Pulmonary Vasoconstriction
Swenson, E. R. (2013) · High Altitude Medicine & Biology · doi:10.1089/ham.2013.1010 · Cited by 190
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190
Self-citationTargeting Mechanosensitive Transcription Factors in Atherosclerosis
Niu, N., Xu, S., Xu, Y., Little, P. J., & Jin, Z.-G. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.02.004 · Cited by 186
Hypoxia-inducible factors and innate immunity in liver cancer
Yuen, V. W.-H., & Wong, C. C.-L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137553 · Cited by 183
“An elegant drug library screening study in a human HCC cell line identified digoxin as an effective HIF-1 inhibitor (130).”
BackgroundPlatz, E. A., Yegnasubramanian, S., Liu, J. O., Chong, C. R., Shim, J. S., Kenfield, S. A., Stampfer, M. J., Willett, W. C., Giovannucci, E., & Nelson, W. G. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0020 · Cited by 184
Self-citationHypoxia: The Cornerstone of Glioblastoma
Domènech, M., Hernández, A., Plaja, A., Martínez-Balibrea, E., & Balañà, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212608 · Cited by 173
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics
Kirtonia, A., Gala, K., Fernandes, S. G., Pandya, G., Pandey, A. K., Sethi, G., Khattar, E., & Garg, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.04.006 · Cited by 172
Zeng, Z., Zhao, Y., Chen, Q., Zhu, S., Niu, Y., Ye, Z., Hu, P., Chen, D., Xu, P., Chen, J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01960-w · Cited by 170
Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment
Lu, H., Chen, I., Shimoda, L. A., Park, Y., Zhang, C., Tran, L., Zhang, H., & Semenza, G. L. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.001 · Cited by 168
Self-citationQuaranta, V., Rainer, C., Nielsen, S. R., Raymant, M. L., Ahmed, M. S., Engle, D. D., Taylor, A., Murray, T., Campbell, F., Palmer, D. H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3876 · Cited by 168
Xu, X., Tan, X., Tampe, B., Sanchez, E., Zeisberg, M., & Zeisberg, E. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.636944 · Cited by 168
“To further substantiate the link among hypoxia, Hif1 , and EndMT, we next explored the impact of digoxin, an inhibitor of Hif1 protein translation (30) (Fig.”
BackgroundXin, X., Rodrigues, M., Umapathi, M., Kashiwabuchi, F., Ma, T., Babapoor-Farrokhran, S., Wang, S., Hu, J., Bhutto, I., Welsbie, D. S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217091110 · Cited by 164
“Interestingly, GFAP expression was not affected by administration of digoxin, an inhibitor of HIF-1α translation (17), suggesting that GFAP expression is a result of Müller cell injury from hypoxia but independent of HIF-1α transcriptional activity (Fig.”
BackgroundSelf-citationTranscription Factors in Cancer Development and Therapy
Vishnoi, K., Viswakarma, N., Rana, A., & Rana, B. (2020) · Cancers · doi:10.3390/cancers12082296 · Cited by 164
“Digoxin (a cardiac glycoside), used for treating congestive heart failure and arrhythmias, also inhibit HIF-1α synthesis and show anti-cancer effects [157] and is in phase II of a clinical trial.”
BackgroundDai, Z., Zhu, M. M., Peng, Y., Machireddy, N., Evans, C. E., Machado, R., Zhang, X., & Zhao, Y.-Y. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2079oc · Cited by 162
HIF1α Protein Stability Is Increased by Acetylation at Lysine 709
Geng, H., Liu, Q., Xue, C., David, L. L., Beer, T. M., Thomas, G. V., Dai, M.-S., & Qian, D. Z. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.400697 · Cited by 157
“1) is under the control of hypoxia and HIF-1 and the Renilla luciferase gene is constitutive (30, 31).”
BackgroundSelf-citationHu, K., Babapoor-Farrokhran, S., Rodrigues, M., Deshpande, M., Puchner, B., Kashiwabuchi, F., Hassan, S. J., Asnaghi, L., Handa, J. T., Merbs, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6868 · Cited by 148
“com/oncotarget hypoxia-induced HIF-1α protein accumulation [23].”
Self-citationBosch‐Morell, F., Mérida, S., & Návea, A. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/750637 · Cited by 166
The role of hypoxia in pancreatic cancer: a potential therapeutic target?
Erkan, M., Kurtoğlu, M., & Kleeff, J. H. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1117386 · Cited by 165
“synthesis effectively at a relatively low concentration, but there is no registered clinical trial testing this hypothesis.[115] An agent that has been shown to”
BackgroundGlycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response
Gill, K. S., Fernandes, P., O’Donovan, T. R., McKenna, S. L., Doddakula, K., Power, D. G., Soden, D. M., & Forde, P. F. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.06.005 · Cited by 163
Vadlapatla, R. K., Vadlapudi, A. D., & Mitra, A. K. (2013) · Current Drug Targets · doi:10.2174/13894501113149990015 · Cited by 157
“Digoxin [209]”
Sodium homeostasis in the tumour microenvironment
Leslie, T. K., James, A. D., Zaccagna, F., Grist, J. T., Deen, S. S., Kennerley, A. J., Riemer, F., Kaggie, J. D., Gallagher, F. A., Gilbert, F. J., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.07.001 · Cited by 159
Saha, T., & Lukong, K. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.856974 · Cited by 153
Rodrigues, M. W., Xin, X., Jee, K. J., Babapoor-Farrokhran, S., Kashiwabuchi, F., Ma, T., Bhutto, I. A., Hassan, S. J., Daoud, Y. J., Barañano, D. E., et al. (2013) · Diabetes · doi:10.2337/db13-0014 · Cited by 151
Self-citationChemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness
Lu, H., Xie, Y., Tran, T. M. L., Lan, J., Yang, Y., Murugan, N. L., Wang, R., Wang, Y. J., & Semenza, G. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138577 · Cited by 144
Self-citationMolecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment
Justus, C., Sanderlin, E. J., & Yang, L. V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160511055 · Cited by 152
“Some chemicals such as Acriflavine and Digoxin have been developed to inhibit HIF-1 dimerization and synthesis, thereby blocking tumor growth and vascularization [200,201].”
BackgroundEffects of hypoxia on human cancer cell line chemosensitivity
Strese, S., Fryknäs, M., Larsson, R., & Gullbo, J. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-331 · Cited by 136
“stoma cell line [43]”
Hypoxia and Mucosal Inflammation
Colgan, S. P., Campbell, E. L., & Kominsky, D. J. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044231 · Cited by 132
Wei, H., Bedja, D., Koitabashi, N., Xing, D., Chen, J., Fox-Talbot, K., Rouf, R., Chen, S., Steenbergen, C., Harmon, J. W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202081109 · Cited by 130
“Treatment of WT mice with digoxin, which inhibits HIF-1α synthesis (25), also induced heart failure 1 wk after TAC (Fig.”
BackgroundSelf-citationRetractedLequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01846-x · Cited by 129
“Digoxin and other cardiac glycosides that inhibit HIF-1α protein synthesis blocked tumor growth [22].”
BackgroundGuillot, A., Hamdaoui, N., Bizy, A., Zoltani, K., Souktani, R., Zafrani, E.-S., Mallat, A., Lotersztajn, S., & Lafdil, F. (2014) · Hepatology · doi:10.1002/hep.26598 · Cited by 127
“Hypoxia-inducible factor (HIF)21a is a transcriptional factor involved in BDL-induced liver fibrosis,(28) and its expression is down-regulated in digoxin-treated Hep3B cells.(29) Therefore, we wondered whether antifibrotic effects of digoxin could be mediated through inhibition of Hif1a in Th17 cells.”
Background
Metadata
- Authors
- Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O., & Semenza, G. L.
- Affiliations
- Johns Hopkins University (US)
- Department of Oncology,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-12-16
- Volume
- 105
- Issue
- 50
- Pages
- 19579-19586
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2604945
- OpenAlex
- W2135664375
- Semantic Scholar
- ad3fa6ccad907da0a52a0b821d2be70006a9b6fd
- Cited by
- 624
- References
- 40
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 23 · 2023: 24 · 2022: 35 · 2021: 39 · 2020: 38 · 2019: 34 · 2018: 34 · 2017: 50 · 2016: 42 · 2015: 37 · 2014: 52 · 2013: 57 · 2012: 38
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Flight Attendant Medical Research Institute
- Johns Hopkins University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- digoxin, cardiac glycosides, HIF-1α, HIF-1, tumor growth inhibition, drug screening, ouabain, proscillaridin A, tumor xenografts, cancer therapy
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Cardiac Glycosides, Digoxin, Humans, Transcription, Genetic, Transfection, Protein Biosynthesis, Mice, SCID, Genes, Reporter, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Luciferases, Firefly, Mice, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.